The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Brief Title: A Study of LY2880070 in Participants With Advanced or Metastatic Cancer
Official Title: A Phase 1b/2a Three-Part Open-Label Multicenter Study to Evaluate the Safety and Efficacy of LY2880070 as Monotherapy and in Combination With Gemcitabine in Patients With Advanced or Metastatic Cancer
Study ID: NCT02632448
Brief Summary: The main purpose of this 3-part study is to evaluate the safety and efficacy of the study drug known as LY2880070 in participants with advanced or metastatic solid tumors.
Detailed Description:
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Dana Farber Cancer Institute, Boston, Massachusetts, United States
Karmanos Cancer Institute, Detroit, Michigan, United States
Tom Baker Cancer Centre, Calgary, Alberta, Canada
Cross Cancer Institute, Edmonton, Alberta, Canada
BC Cancer Agency, Vancouver, British Columbia, Canada
Ottawa Hospital Cancer Centre, Ottawa, Ontario, Canada
University Health Network - Princess Margaret Hospital, Toronto, Ontario, Canada
Jewish General Hospital, Montreal, Quebec, Canada
McGill University Health Centre, Montreal, Quebec, Canada
Centre Hospitalier de l'Université de Montréal, Montréal, Quebec, Canada
General Hospital Zadar, Zadar, , Croatia
University Hospital Centre Zagreb, Zagreb, , Croatia
Centrum Onkologii im. prof. F. Łukaszczyka, Bydgoszcz, , Poland
Uniwersyteckie Centrum Kliniczne Osrodek Badan Klinicznych Wczesnych Faz, Gdańsk, , Poland
Centrum Badań Klinicznych Jagiellońskie Centrum Innowacji sp. z o. o., Kraków, , Poland
Szpital Specjalistyczny im. L. Rydygiera w Krakowie sp. z o. o., Kraków, , Poland
Name: Email: Darcy.Vincett@ozmosisresearch.ca
Affiliation: Esperas Pharma Inc.
Role: STUDY_DIRECTOR